Seattle Genetics is the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. In addition to one marketed product, we are advancing a deep product pipeline designed to address significant unmet medical needs.

ADCETRIS: Broad Global Development Plan
Our lead program, ADCETRIS® (brentuximab vedotin) is the first in a new class of ADCs and, in collaboration with Takeda Pharmaceutical Company Limited, is approved in more than 60 countries. We are conducting a broad clinical development program evaluating its potential to become the foundation of treatment for CD30-expressing lymphomas.

SGN-CD33A: Emerging Phase 3 Program
We also are advancing vadastuximab talirine (SGN-CD33A; 33A), a novel ADC that is expected to advance into a phase 3 trial for acute myeloid leukemia in 2016. AML is a significant unmet need.